European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Valneva Austria GmbH, Vienna, Austria

Watch
Valneva Austria GmbH

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Create Dossier
Valneva Austria GmbH

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Risk report
Valneva Austria GmbH
Risk Level Evaluation Source
Sanctioned (?)
Anti-trust proceedings (?)

Name

Valneva Austria GmbH
INTERCELL Austria AG

Identification

Fb
Firmenbuch 389960x
Lei
529900JDYES6I2HHT776
EUID
ATBRA.389960-000

Address

Campus Vienna Biocenter 3, 1030 Wien, Austria

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information · Proxy policies Premium
Premium
2Managing Director
2Member of the Executive Board
8Authorized signatory (ppa)
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

DATA SERVICES

Unlock the full potential of processed company data with our API or Quarterly Exports.

Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
One known shareholder
Portfolio and Investments
2 known active shareholdings
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Revenue
Return on sales
Equity
Equity ratio
Employee number
Revenue per employee
Taxes
Tax ratio
Cash on hand
Receivables
Liabilities
Cost of materials
Wages and salaries
Average salaries per employee
Pension provisions
Real estate
Number of public fundings
Patents
Total public funding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

1 May 2026 in Hor
EU funding (€233,250): EUROPEAN-AFRICAN VACCINE INITIATIVE (EAVI): ACCELERATING PREVENTIVE MEASURES AGAINST CHIKUNGUNYA VIRUS IN SUB-SAHARAN AFRICA
29 Apr 2026
Patent: Mutated fragments of Ospa and methods and uses related to it
29 Apr 2026
Patent: Improved methods for the production of a lipidized protein
12 Feb 2026
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
23 Aug 2025
Annual report for the year ending 31/12/2024 · Balance sheet for 31/12/2024
5 Jul 2025
No longer Authorized signatory (ppa): Franck Grimaud
18 Jun 2025
Patent: Mutated fragments of Ospa and methods and uses related to it
18 Jan 2025
Annual report for the year ending 31/12/2023
27 Sept 2024
Authorized signatory (ppa): Johanna Schuitemaker, Kendra Wergin
3 Sept 2024
No longer Authorized signatory (ppa): Frédéric Jacotot
Year 2024 in Epobase
4 European patent filings: Aluminium Compounds for USE in Therapeutics and Vaccines …
10 Oct 2023
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
23 Sept 2023
Managing Director: Dipal Patel
Year 2023 in Epobase
4 European patent filings: Multivalent Ospa Polypeptides and Methods and Uses Relating Thereto …
31 Mar 2023
Authorized signatory (ppa): S. Eder-Lingelbach
31 Jan 2023
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021
26 Jan 2023
Word figurative mark: “intercell SMART VACCINES“
26 Jan 2023
Wordmark: “AIP (Antigen Identification Program)“
14 Sept 2022
Patent: Aluminum compounds for use in therapeutics and vaccines
Year 2022 in Euipotm
5 wordmarks: IXCORVA, IXFIDEN, IXFIDENTIA, IXFIDENZ, IXPONSAR
2 Feb 2022
Managing Director: Peter Georg Bühler
11 Oct 2021
Wordmark: “INTERCELL“
25 Sept 2021
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020
20 May 2021
Wordmark: “VLA2001“
Year 2021 in Epobase
8 European patent filings: Improved Methods of Producing a Lipidated Protein …
5 Dec 2020
Managing Director: Juan C. Jaramillo · No longer Managing Director: Wolfgang Bender, David Lawrence
15 Oct 2020
Wordmark: “INTERCELL“
29 Sept 2020
Annual report for the year ending 31/12/2019
9 Sept 2020
Patent: Inactivation procedure for viruses
4 Mar 2020
Patent: Mutated OspA fragments and methods and uses related thereto
4 Oct 2019
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018
25 Jul 2019
Wordmark: “TRANSVAX“
5 Jun 2019
Patent: Mutant Fragments of Ospa and Methods and Uses Relating Thereto
5 Oct 2018
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
3 Oct 2018
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
5 Sept 2018
Patent: Mutated ospa fragments, methods thereof and uses thereof
17 Nov 2017
Annual report for the year ending 31/12/2016 (only announcement)
19 Oct 2017
Managing Director: Wolfgang Bender, Frédéric Jacotot, David Lawrence
11 Oct 2017
Patent: Aluminium Compounds for USE in Therapeutics and Vaccines
21 Apr 2017
No longer Managing Director: Reinhard Kandera
1 Apr 2017
Authorized signatory (ppa): Manfred Tiefenbacher
25 Jan 2017
Patent: Isolated Polypeptide of Toxin A and Toxin B FROM C. Difficile and Use Thereof
Year 2016 in Epobase
9 European patent filings: Zika Virus Purification …
5 Oct 2016
Annual report for the year ending 31/12/2015 (only announcement)
22 Jul 2016
Firmenbuch - Vollzug - Republik Österreich vertreten durch das BMJ
1 Jul 2016
Utility patent: Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen
11 Nov 2015
Merger: Elatos GmbH
9 Oct 2015
Annual report for the year ending 31/12/2014 (only announcement)
15 Jun 2015
Wordmark: “IC41“
15 Jun 2015
Wordmark: “IC51“
15 Jun 2015
Wordmark: “JE-PIV“
10 Jun 2015
Patent: A Method for Identification, Isolation and Production of Antigens to a Specific Pathogen
20 Dec 2014
Shareholder: Valneva SE · Capital: €10.1M
14 Oct 2014
Annual report for the year ending 31/12/2013 (only announcement)
30 Apr 2014
Patent: Streptococcus Pyogenes Antigens
27 Feb 2014
Utility patent: Aluminum compounds for use in therapeutics and vaccines
21 Jan 2014
Utility patent: Aluminum compounds for use in therapeutics and vaccines
3 Dec 2013
Resolution of the Annual General Meeting of 26.11.2013 Amendment of the Memorandum of Association in point 8.
18 Sept 2013
Patent: Improved Vaccines
31 Aug 2013
MD: Franck Grimaud, Reinhard Kandera, Thomas Lingelbach · ppa: Olivier Jankowitsch · No longer CxO (4) · No longer SB (5) · No longer Dep. Chair SB (1) · No longer Chair SB (1) …
16 Jul 2013 as INTERCELL Austria AG
Member of the Supervisory Board (1) · Shareholder: Valneva SE · No longer Shareholder: Intercell AG
14 Jun 2013
Figurative mark
5 Jun 2013 as INTERCELL Austria AG
Member of the Executive Board (2) · Member of the Supervisory Board (3)
28 May 2013 as INTERCELL Austria AG
Annual report for the year ending 31/12/2012 (only announcement)
15 May 2013 as INTERCELL Austria AG
Resolution of the Annual General Meeting dated 27.02.2013 demerger to absorb a part of the assets of the INTERCELL AG ( …
19 Apr 2013 as INTERCELL Austria AG
CxO: Reinhard Kandera, Thomas Lingelbach · ppa: Olivier Jankowitsch · No longer Chair SB: Thomas Lingelbach · No longer CxO: Olivier Jankowitsch · No longer Dep. Chair SB: Reinhard Kandera …
20 Dec 2012 as INTERCELL Austria AG
Reg­is­tra­tion: 20/12/2012 · CxO: Olivier Jankowitsch · Chair SB: Thomas Lingelbach · Dep. Chair SB: Reinhard Kandera · SB (1) · SH: Intercell AG · Address · Deadline for annual balance: 31.12. …
Year 2012 in Epobase
5 European patent filings: Aluminium Compounds for USE in Therapeutics and Vaccines …
6 Dec 2012
Utility patent: Aluminium-Verbindungen zur Verwendung in Therapeutika und Impfstoffen
There are no publications matching your search.

Mentions

30 Jul 2025 in Ler
Direct parent
30 Jul 2025 in Ler
Ultimate parent
13 May 2025 in Psc
Shareholding, Voting rights: Valneva Scotland Ltd
28 Nov 2023 in Bmjfbv
Shareholding: VBC 3 Errichtungs GmbH
6 Feb 2013 in Wzfma
Shareholding: Elatos GmbH
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.